NEW YORK (GenomeWeb News) — Mirus Bio has received a two-year, $900,000 Phase II Small Business Innovative Research grant to develop its microRNA-labeling technology for clinical research and “potential diagnostic applications,” the company said today.
The Madison, Wis.-based miRNA and siRNA transfection company said it will use the money to develop products that will study the link between miRNAs and undisclosed diseases that it will eventually “enable diagnostic testing for miRNAs as biomarkers for disease.”
Mirus said it will market products resulting from the research. The company currently sells a Label IT miRNA kit that is used in microarray analysis.
Mirus will conduct the work in collaboration with Gregory Tsongalis, director of molecular pathology at the Dartmouth Hitchcock Medical Center in Lebanon, NH, it said.
The grant came from the National Institute of General Medical Sciences.